
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. has a strong outlook driven by the promising clinical development of its product candidate, pemvidutide, which targets metabolic dysfunction-associated steatohepatitis (MASH) through a dual receptor agonist mechanism. Recent industry movements, such as Novo’s acquisition of Akero Therapeutics, suggest growing confidence in the MASH therapeutic landscape and highlight the potential for pemvidutide to deliver significant metabolic and hepatic benefits without the complexities of combination dosing. Altimmune’s advancements, including leadership enhancements and robust clinical signals supporting pemvidutide’s tolerability and effectiveness, position the company well amidst a shift towards multi-mechanism strategies in treating metabolic and liver diseases.
Bears say
Altimmune Inc faces numerous risks that contribute to a negative outlook on its stock, primarily stemming from clinical development challenges associated with its product candidate, pemvidutide. The company is also exposed to competitive pressures, commercialization hurdles, and reimbursement uncertainties that could hinder market access and profitability. Additionally, potential disruptions due to external factors such as the ongoing geopolitical situation in Eastern Europe and the lingering effects of COVID-19 present further headwinds that could adversely affect the company's clinical trial timelines and overall financial stability.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares